UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 166 filers reported holding UNIQURE NV in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,819,000 | -6.8% | 54,000 | 0.0% | 0.01% | -25.0% |
| Q4 2020 | $1,951,000 | -1.9% | 54,000 | 0.0% | 0.02% | -23.8% |
| Q3 2020 | $1,989,000 | -18.2% | 54,000 | 0.0% | 0.02% | -22.2% |
| Q2 2020 | $2,433,000 | -5.0% | 54,000 | 0.0% | 0.03% | -22.9% |
| Q1 2020 | $2,562,000 | -40.4% | 54,000 | -10.0% | 0.04% | -7.9% |
| Q4 2019 | $4,300,000 | +82.0% | 60,000 | 0.0% | 0.04% | +72.7% |
| Q3 2019 | $2,362,000 | -49.6% | 60,000 | 0.0% | 0.02% | -47.6% |
| Q2 2019 | $4,689,000 | +31.0% | 60,000 | 0.0% | 0.04% | +40.0% |
| Q1 2019 | $3,579,000 | +107.0% | 60,000 | 0.0% | 0.03% | +87.5% |
| Q4 2018 | $1,729,000 | -20.8% | 60,000 | 0.0% | 0.02% | +6.7% |
| Q3 2018 | $2,183,000 | -42.2% | 60,000 | -40.0% | 0.02% | -42.3% |
| Q2 2018 | $3,780,000 | +28.7% | 100,000 | -20.0% | 0.03% | +23.8% |
| Q1 2018 | $2,938,000 | +20.0% | 125,000 | 0.0% | 0.02% | +31.2% |
| Q4 2017 | $2,449,000 | – | 125,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |